Recs

0

Here's Why Aratana Therapeutics Inc. Is Getting Clobbered

What happened

After reporting fourth-quarter earnings that came up short of expectations, shares of Aratana Therapeutics  (NASDAQ: PETX  ) , a biotech company focused on pet health, fell by 21% as of 1:40 p.m. Tuesday.

So what

Here's a review of the headline numbers from the fourth quarter:

  • Revenue for the period came in at $292,000, which was primarily generated from sales of the company's drug Nocita. This compound became commercially available in late 2016 and is used as a local post-operative analgesia for ligament surgery in dogs. By contrast, Wall Street was expecting $923,000 in total revenue for the quarter.
  • Net loss was $23.3 million, or $0.64 per share. This figure was much higher than the $12.9 million net loss that was recorded in the year-ago period and also exceeded the $0.43 loss that analysts were expecting. However, it is worth noting that the company recorded a $10.7 million writedown on inventory and intangible assets during the fourth quarter.
A man stacking coins in taller piles from left to right.

Image source: Getty Images.

And for the full year 2016:

  • Total revenue was $38.6 million. A large majority of this total was generated from a substantial upfront payment related to the collaboration agreement with Elanco Animal Health, a division of Eli Lilly.
  • Net loss was $33.6 million, or $0.95 per share. The total impairment charges for the year were $15.1 million.
  • At year end, Aratana's cash balance was $88.7 million. Management believes this will be enough capital to fund operations through the first quarter of 2018.

The lower than hoped for quarterly sales and higher than expected loss appear to be the primary reasons behind Tuesday's drubbing.

Now what

This is the second time this quarter that Aratana's stock has taken a big plunge. Shares also dropped in early February after management said the FDA's Center for Veterinary Medicine wanted more information related to the company's transfer of its drug Entyce to a new manufacturer. The request is expected to delay the drug's launch until late 2017, which means it is going to take Aratana more than a year to bring this drug to market. That's not good news for any company, let alone a cash-strapped, small-cap biotech.

With losses continuing to pile up, Aratana is likely going to have to raise capital sometime soon. Given the stock's recent drubbing, hitting up shareholders for extra cash is likely to be an unappealing option. That makes me think potential investors should remain on the sidelines until we know more about the company's financial plans.

10 stocks we like better than Aratana Therapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Aratana Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of February 6, 2017


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 4008278, ~/Articles/ArticleHandler.aspx, 3/23/2017 12:21:10 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
Change up DOW 20738.1 76.8 0.4%
Change up S&P 500 2356.8 8.4 0.4%
Change up NASD 5839.9 18.3 0.3%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

3/23/2017 12:05 PM
PETX $5.25 Up +0.04 +0.77%
Aratana Therapeuti… CAPS Rating: ***
LLY $85.01 Up +0.65 +0.77%
Eli Lilly and Co. CAPS Rating: ****

Article registration testing
VISIBLE INTERNALLY ONLY AND ONLY WORKS WITH UNREGISTERED VISITORS

Revisit this page

Clear article's cache and revisit this page

Or, visit the current page, forcing Test ID to article:interrupt:106919 and

Tookie Value = 17601997857325810227506131718793

Advertisement